Search | Clinical Trials Finder

Conditions: Prostate Cancer, Prostatic Neoplasms
Interventions: Docetaxel, Imatinib Mesylate; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 3
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: PF-07248144, Fulvestrant, Everolimus, Exemestane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 102
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more

Conditions: Rheumatoid Arthritis, Healthy
Interventions: Etanercept; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dwarfism, Turner's Syndrome
Interventions: Humatrope, Oxandrolone; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 10 Years to 14 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2007
U.S. locations: 2
States / cities: Bethesda, Maryland • Philadelphia, Pennsylvania

Conditions: Acromegaly
Interventions: Debio 4126, Placebo; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 7 more

Conditions: Growth Hormone Deficiency, Dwarfism
Interventions: Dextromethorphan and Caffeine; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 4 Years to 14 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 4
States / cities: San Diego, California • Louisville, Kentucky • Kansas City, Missouri + 1 more

Conditions: AIDS, HIV Infections
Interventions: recombinant human growth hormone, placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tendinopathy, Rheumatic Diseases
Interventions: Ultrasound-guided platelet-rich-plasma (PRP) injection, Platelet-Rich Plasma (PRP); Procedure
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Growth Hormone Deficiency (GHD)
Interventions: LUM-201, Matched Placebo (Capsules); Drug · Other
Lead sponsor: Lumos Pharma; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 30
States / cities: Birmingham, Alabama • Madera, California • Orange, California + 27 more

Conditions: Anemia, Fatigue, Prostate Cancer
Interventions: epoetin alfa, dexamethasone; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 140
States / cities: Modesto, California • Aurora, Colorado • Boulder, Colorado + 92 more

Conditions: Osteoarthritis, Articular Cartilage, Musculoskeletal Disorders
Interventions: Platelet-Rich Plasma (PRP) Injections, Centrifuge, Control saline injection; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Idiopathic Short Stature
Interventions: Genotropin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 3 Years to 10 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 43
States / cities: Little Rock, Alaska • Little Rock, Arkansas • Los Angeles, California + 32 more

Conditions: Systemic Lupus Erythematosus
Interventions: Leukapheresis, Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT), Autologous CD34+HPC transplantation (HSCT), Plasmapheresis, Rabbit anti-thymocyte globulin, Methylprednisolone, Growth colony stimulating factor (G-CSF), Corticosteroids, Mycophenolate mofetil, Azathioprine, Intravenous immunoglobulin, Methotrexate, Rituximab, Leflunomide; Procedure · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 5
States / cities: La Jolla, California • Los Angeles, California • Chicago, Illinois + 2 more

Conditions: Acromegaly
Interventions: lanreotide; Drug
Lead sponsor: Saint John's Cancer Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Growth Hormone Deficiency
Interventions: LUM-201; Drug
Lead sponsor: Lumos Pharma; Industry
Eligibility: 5 Years to 14 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Iowa City, Iowa • Worcester, Massachusetts • Kansas City, Missouri + 3 more

Conditions: Growth Hormone Deficiency
Interventions: NuSpin, Somatropin; Device · Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 2 Years to 14 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 11 more

Conditions: Growth Hormone Insensitivity Syndrome (GHIS), Laron Syndrome
Interventions: rhIGF-I/rhIGFBP-3; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 2 Years to 18 Years
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Somatropin (recombinant human growth hormone); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Growth Hormone Deficiency
Interventions: No intervention; Drug
Lead sponsor: Ascendis Pharma Endocrinology Division A/S; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 27
States / cities: Phoenix, Arizona • Orange, California • Sacramento, California + 23 more

Conditions: Growth Hormone Deficiency in Children
Interventions: Somapacitan, Norditropin®; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Up to 11 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • Madera, California + 24 more

Conditions: Diet Modification, Lung Cancer
Interventions: Special Diet Therapy (low-carb), Special Diet Therapy (low-fat), Special Diet Therapy (USDA control); Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Growth Hormone Insensitivity Syndrome
Interventions: mecasermin; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2011
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Breast Cancer
Interventions: Pertuzumab, Trastuzumab, Aromatase Inhibitor, Induction Chemotherapy; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 21
States / cities: Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 17 more

Conditions: Estrogen Receptor Positive, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Fulvestrant, Laboratory Biomarker Analysis, Lapatinib Ditosylate, Placebo Administration; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 368
States / cities: Little Rock, Arkansas • Arroyo Grande, California • Burbank, California + 259 more

Search by objective public record fields.

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept

The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

rhGH Therapy on Hepatic Drug Metabolism

Physiologic Growth Hormone Effects in HIV Lipodystrophy

Performance-Enhancing Effects of Platelet-Rich Plasma (PRP) Injections

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer

Platelet Rich Plasma Injections In Young And Old Human Subjects

Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature

Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)

A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)

A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device

IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome

Growth Hormone to Increase Immune Function in People With HIV

A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)

Reducing Insulin, Growth Hormones, and Tumors

Long-Term Treatment With rhIGF-1 in GHIS

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive